Healthleap, a startup developing an AI platform for identifying undiagnosed patient conditions, has secured $38 million in seed and Series A funding. The financing round included $8 million in seed capital co-led by Sequoia Capital and First Round Capital, alongside a $30 million Series A round led by Hummingbird Ventures.
Founded in 2022 by siblings Jemima and Josiah Meyer, the company transitioned from a clinical nutrition tool to a broader platform. The software integrates with electronic health records to analyze both structured data, such as lab results and vitals, and unstructured clinical notes to flag potential risks like malnutrition, delirium, and aspiration pneumonia.
The platform is currently utilized in over 50 hospitals, including major systems such as Penn Medicine, Cedars-Sinai, and Emory Healthcare. The company reports that its customer base has expanded from three partners to more than 50 over the past year, with revenue increasing by more than 10 times during the same period.
Healthleap utilizes a three-year contract model based on licensed bed counts and outcome-based pricing. The company claims that every customer has achieved a return on investment of at least 5 times the contract price. For instance, the Hospital of the University of Pennsylvania reported an annualized financial impact of $23.8 million.
The startup intends to allocate the new capital toward engineering, product development, sales, and customer success. Future expansion plans include increasing the number of detectable health conditions to over 40 and extending the platform's reach into outpatient and home care settings.
